GlobalRPh RX List - ZORTRESS
- Product / population
- ZORTRESS transplant formulation and combination context; not AFINITOR oncology guidance.
- Renal measure
- Qualitative renal impairment; exposure-guided transplant combination monitoring.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
The source does not require adjustment for renal impairment alone. That does not remove nephrotoxicity from the transplant combination: reduced cyclosporine exposure is required with everolimus, and the label uses everolimus trough monitoring with a 3-8 ng/mL target. Those co-therapy and monitoring instructions belong to the transplant regimen; do not transfer them to oncology AFINITOR or use a renal no-adjustment statement to leave cyclosporine unreviewed.